文献速递临床试验与 GCP流行病学与生物统计

新生儿阿片戒断症状导向给药随机临床试验

Symptom-Based Dosing for Neonatal Opioid Withdrawal: The OPTimize NOW Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

该集群交叉随机临床试验纳入626名胎龄≥36周的新生儿阿片戒断综合征患儿,比较症状导向给药与计划性阿片减量方案。在ESC照护队列中,症状导向给药组达到出院医学准备时间显著短于计划减量组(9.18 vs 11.61天;aMR 0.79,95%CI 0.65-0.96),但两组启动药物治疗风险和住院时长无差异。

要点

  • 症状导向给药可缩短ESC照护下NOWS患儿达到出院医学准备的时间。
  • 症状导向给药未增加启动药物治疗的风险或延长住院时长。
  • 症状导向组35%患儿因戒断严重需转为计划性阿片给药。

核心结论

  • 在ESC照护的NOWS患儿中,症状导向给药较计划性阿片减量缩短达到出院医学准备时间。
  • 症状导向给药未增加启动药物治疗风险或住院时长。

研究设计与样本

  • 集群交叉随机临床试验,含导入期,23家美国医院参与。
  • 15家医院采用ESC照护,8家采用Finnegan评分照护,使用各自首选阿片类药物。
  • 纳入胎龄≥36周且存在药物治疗风险的NOWS患儿,2024年3月25日至2025年4月9日入组,共626名。
  • 主要分析队列为ESC照护的383名患儿,Finnegan队列243名为计划次要结局。

主要发现

  • ESC队列中症状导向组与计划减量组达到出院医学准备时间分别为9.18天和11.61天(aMR 0.79,95%CI 0.65-0.96)。
  • 两组启动药物治疗风险分别为0.4和0.41(aRR 0.99,95%CI 0.77-1.27)。
  • 两组住院时长分别为10.91天和12.09天(aMR 0.9,95%CI 0.72-1.13)。
  • 症状导向组35%(95%CI 25%-45%)因戒断严重需计划性阿片给药。
  • Finnegan队列中两组达到出院医学准备时间(15.99 vs 17.56天;aMR 0.91,95%CI 0.72-1.15)和住院时长(17.38 vs 19.39天;aMR 0.9,95%CI 0.69-1.16)无显著差异。

临床怎么用

  • 对ESC照护下需药物治疗的NOWS患儿,可考虑症状导向给药以缩短出院准备时间。
  • 症状导向给药时需监测戒断严重度,部分患儿仍需转为计划性阿片给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Infants with neonatal opioid withdrawal syndrome (NOWS) who receive pharmacologic treatment are traditionally treated with a scheduled opioid taper. An alternate approach, symptom-based dosing, may better align treatment with withdrawal severity. OBJECTIVE: To compare time from birth to medical readiness for discharge for infants with moderate to severe withdrawal treated with either a symptom-based dosing or scheduled opioid taper approach. DESIGN, SETTING, AND PARTICIPANTS: In this cluster, crossover randomized clinical trial with run-in period, 23 US hospitals cared for infants using the Eat, Sleep, Console approach (ESC) or Finnegan-based care (a comprehensive scoring system to quantify severity of symptoms; 15 ESC and 8 Finnegan hospitals) and their preferred primary opioid. Opioid dosing was guided by study-approved, site-specific algorithms. Infants with NOWS with a gestational age at birth of at least 36 weeks and at risk for pharmacologic treatment were enrolled between March 25, 2024, and April 9, 2025, with the last 3-month assessment on July 15, 2025. Sample size analyses were conducted between August 1, 2024, and September 23, 2024. INTERVENTION: Sites were randomized to 1 of 2 sequences: (1) symptom-based dosing followed by scheduled opioid taper or (2) scheduled opioid taper followed by symptom-based dosing. MAIN OUTCOME AND MEASURE: Time from birth to medical readiness for discharge. RESULTS: Of the 626 enrolled infants (mean [SD] gestational age, 38 [1] weeks; 49% male), 383 were cared for with ESC (primary outcome cohort). The mean time to medical readiness for discharge was significantly shorter in the symptom-based dosing group compared with the scheduled opioid taper group (9.18 vs 11.61 days; adjusted mean ratio [aMR], 0.79 [95% CI, 0.65-0.96]). There was no difference in the risk for initiation of pharmacologic treatment (0.4 vs 0.41; adjusted risk ratio, 0.99 [95% CI, 0.77-1.27]) or length of stay (10.91 vs 12.09 days; aMR, 0.9 [95% CI, 0.72-1.13]) between groups. For infants in the symptom-based group, 35% (95% CI, 25%-45%) required scheduled opioid dosing due to withdrawal severity that was not controlled with intermittent dosing. In the Finnegan cohort (n = 243; planned secondary outcome), there were no significant differences in time to medical readiness for discharge (15.99 vs 17.56 days; aMR, 0.91 [95% CI, 0.72-1.15]) or length of stay (17.38 vs 19.39 days; aMR, 0.9 [95% CI, 0.69-1.16]). The inpatient composite safety outcome occurred rarely (in the ESC cohort, 3 of 188 in the symptom-based dosing vs 2 of 195 in the scheduled opioid taper groups). CONCLUSIONS AND RELEVANCE: Symptom-based dosing decreased time to medical readiness for discharge compared with a scheduled opioid taper approach among infants cared for with ESC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05980260.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Devlin LA, Babineau DC, Merhar SL, et al. Symptom-Based Dosing for Neonatal Opioid Withdrawal: The OPTimize NOW Randomized Clinical Trial. JAMA. 2026. PMID: 42033722. doi:10.1001/jama.2026.5782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。